Structure of Prexasertib
CAS No.: 1234015-52-1
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
LY2606368 is a potent and selective ATP competitive inhibitor (IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.
Synonyms: Ly2606368; ACR 368
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1234015-52-1 |
Formula : | C18H19N7O2 |
M.W : | 365.39 |
SMILES Code : | N#CC1=NC=C(NC2=NNC(C3=C(OC)C=CC=C3OCCCN)=C2)N=C1 |
Synonyms : |
Ly2606368; ACR 368
|
MDL No. : | MFCD25977016 |
InChI Key : | DOTGPNHGTYJDEP-UHFFFAOYSA-N |
Pubchem ID : | 46700756 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Description |
Prexasertib (LY2606368) is distinguished as a highly selective and ATP-competitive second-generation inhibitor of checkpoint kinase 1 (CHK1), possessing a Ki value of 0.9 nM and an IC50 of less than 1 nM. Its ability to inhibit CHK1 with such potency underlines its mechanism of action, which involves causing double-stranded DNA breaks and replication catastrophe, leading to apoptosis. Beyond CHK1, Prexasertib exhibits inhibition against CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM), demonstrating its broad spectrum of action against other kinases involved in cell cycle regulation and tumor growth[1].[2].
|
In Vitro:
Concentration | Treated Time | Description | References |
OVCAR8 | 5.4 nM | 48 hours | Determine the IC50 of Prexasertib on OVCAR8 cells | Oncogene. 2020 Aug;39(33):5520-5535. |
OVCAR5 | 7.5 nM | 48 hours | Determine the IC50 of Prexasertib on OVCAR5 cells | Oncogene. 2020 Aug;39(33):5520-5535. |
OVCAR8R | 3 µM | 48 hours | Determine the IC50 of Prexasertib on resistant OVCAR8R cells | Oncogene. 2020 Aug;39(33):5520-5535. |
OVCAR5R | 3 µM | 48 hours | Determine the IC50 of Prexasertib on resistant OVCAR5R cells | Oncogene. 2020 Aug;39(33):5520-5535. |
CRC-SCs (colorectal cancer stem cells) | 10 nM, 50 nM, 100 nM | 1 hour, 4 hours, 9 hours, 24 hours | Assess the impact of LY2606368 on ATM phosphorylation via RPPA analysis, showing LY2606368 induces ATM phosphorylation in sensitive CRC-SCs. | Gut. 2018 May;67(5):903-917. |
SCLC cell lines | 300 nM | 120 hours | Evaluate the antiproliferative effect of LY2606368 on SCLC cell lines, with IC50 <100 nmol/L in half of the human SCLC cell lines | Cancer Res. 2017 Jul 15;77(14):3870-3884. |
H460 | 50 nM | 19 days | Screen for sgRNAs that increase or decrease cell killing by the CHK1 inhibitor prexasertib | Mol Cell. 2020 Nov 5;80(3):410-422.e6. |
A549 | 100 nM | 19 days | Screen for sgRNAs that increase or decrease cell killing by the CHK1 inhibitor prexasertib | Mol Cell. 2020 Nov 5;80(3):410-422.e6. |
OVCAR8 | 1-40 nM | 24 hours | Increased PARylation was observed even after 24 h exposure at low concentrations | Cell Death Discov. 2024 Jun 11;10(1):278. |
Rh41 (alveolar RMS) | 1 µM | 24 hours | Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. | Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. |
RD (embryonal RMS) | 1 µM | 24 hours | Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. | Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. |
SJCRH30 (alveolar rhabdomyosarcoma) | 1 µM | 24 hours | Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. | Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. |
MG-63 (osteosarcoma) | 1 µM | 24 hours | Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. | Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. |
A673 (Ewing’s sarcoma) | 1 µM | 24 hours | Evaluate the effect of Prexasertib on cell proliferation, results showed Prexasertib significantly inhibited cell proliferation and activated DNA damage response. | Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. |
H69, H446, and RPP/mTmG cells | 1 µM | 24 hours | Evaluated prexasertib-induced cytogenetic stress. Treatment led to a significant increase in MN frequency (p<0.001). | Cancer Discov. 2019 May;9(5):646-661. |
ML-1 | 10 nM | 24 hours | Induced apoptosis, including DNA fragmentation, phosphatidylserine exposure, and cleavage of caspase substrates | Cancer Res. 2021 May 15;81(10):2666-2678. |
THP.1 | 10 nM | 24 hours | Induced apoptosis, including DNA fragmentation, phosphatidylserine exposure, and cleavage of caspase substrates | Cancer Res. 2021 May 15;81(10):2666-2678. |
U937 | 10 nM | 24 hours | Induced apoptosis, including DNA fragmentation, phosphatidylserine exposure, and cleavage of caspase substrates | Cancer Res. 2021 May 15;81(10):2666-2678. |
SKN | 100 nM | 24 hours | To evaluate the effect of Prexasertib on the cell cycle, results showed that 100 nmol/L Prexasertib significantly reduced the number of G1 phase cells and increased the number of S and G2–M phase cells. | Clin Cancer Res. 2022 May 13;28(10):2147-2159. |
SK-LMS-1 | 100 nM | 24 hours | To evaluate the effect of Prexasertib on the cell cycle, results showed that 100 nmol/L Prexasertib significantly reduced the number of G1 phase cells and increased the number of S and G2–M phase cells. | Clin Cancer Res. 2022 May 13;28(10):2147-2159. |
SK-UT-1 | 10 nM | 24 hours | To evaluate the effect of Prexasertib on the cell cycle, results showed that 10 nmol/L Prexasertib was sufficient to induce cell-cycle arrest. | Clin Cancer Res. 2022 May 13;28(10):2147-2159. |
NCI-H460 | 50-100 nM | 24 hours | To evaluate the effect of CHK1 inhibition on replication stress markers | Cell Rep. 2021 Mar 2;34(9):108808. |
A549 | 50-100 nM | 24 hours | To evaluate the effect of CHK1 inhibition on replication stress markers | Cell Rep. 2021 Mar 2;34(9):108808. |
Huh-7 cells | 5 nM | 24 hours | To investigate the effect of Prexasertib on apoptosis in Huh-7 cells, results showed that Prexasertib inhibited CHK1 protein levels and promoted cleaved PARP expression, indicating induction of apoptosis. | Br J Cancer. 2021 Jul;125(1):101-111. |
Hepa1-6 cells | 1 µM | 24 hours | To investigate the effect of Prexasertib on apoptosis in Hepa1-6 cells, results showed that Prexasertib inhibited CHK1 protein levels and promoted cleaved PARP expression, indicating induction of apoptosis. | Br J Cancer. 2021 Jul;125(1):101-111. |
SKOV3 | 1 µM | 30 min to 8 hours | Prexasertib treatment caused increased PARylation of proteins, indicating PARP1/2 activation | Cell Death Discov. 2024 Jun 11;10(1):278. |
OVCAR8 | 1 µM | 30 min to 8 hours | Prexasertib treatment caused increased PARylation of proteins, indicating PARP1/2 activation | Cell Death Discov. 2024 Jun 11;10(1):278. |
TOV112D | 1–10 nM | 3–6 days | To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. | Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. |
ES2 | 1–10 nM | 3–6 days | To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. | Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. |
UWB1.289 | 1–10 nM | 3–6 days | To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. | Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. |
OVCAR3 | 1–10 nM | 3–6 days | To evaluate the cytotoxicity of Prexasertib in ovarian cancer cell lines, results showed that most cell lines were sensitive to Prexasertib with IC50 values of 1–10 nM. | Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. |
Retinal ganglion cells (RGCs) | 10 µM | 4 days | Prexasertib significantly improved RGC survival and promoted neurite outgrowth. | Sci Adv. 2022 Sep 16;8(37):eabq2611. |
Adult rat dorsal root ganglion neurons (DRGN) | 10 µM | 4 days | Prexasertib significantly improved DRGN survival (from 40% to 90%) and promoted neurite outgrowth (neurite length increased from 180 μm to 520 μm). | Sci Adv. 2022 Sep 16;8(37):eabq2611. |
CCRF-CEM SLFN11-del and parental cells | 1 µM | 4 hours | CHK1i treatment for 4 hours induced SLFN11 binding to chromatin and increased the chromatin binding of CDC45 in both parental and SLNF11-del cells | Mol Cell. 2018 Feb 1;69(3):371-384.e6. |
CCRF-CEM cells | 100 nM | 6 hours | To investigate the effect of SLFN11 on chromatin accessibility and IEG transcriptional activation under replication stress. Results showed that SLFN11 enhanced chromatin accessibility and selectively activated IEG transcription. | Cell Rep. 2020 Mar 24;30(12):4137-4151.e6. |
A673 | 1 nM | 6 hours | To evaluate the effect of Prexasertib on CHK1 protein levels and protein synthesis. Results showed that Prexasertib reduced CHK1 protein levels and inhibited protein synthesis. | Mol Cancer Ther. 2018 Dec;17(12):2676-2688. |
TC71 | 1 nM | 6 hours | To evaluate the effect of Prexasertib on CHK1 protein levels and protein synthesis. Results showed that Prexasertib reduced CHK1 protein levels and inhibited protein synthesis. | Mol Cancer Ther. 2018 Dec;17(12):2676-2688. |
EW8 | 1 nM | 6 hours | To evaluate the effect of Prexasertib on CHK1 protein levels and protein synthesis. Results showed that Prexasertib reduced CHK1 protein levels and inhibited protein synthesis. | Mol Cancer Ther. 2018 Dec;17(12):2676-2688. |
Murine SCLC cell lines (RPP/mTmG) | 300 nM | 72 hours | Analyzed cell surface PD-L1 expression by flow cytometry. Prexasertib treatment significantly increased cell surface PD-L1 levels. | Cancer Discov. 2019 May;9(5):646-661. |
Human SCLC cell lines | 300 nM | 72 hours | Analyzed PD-L1 protein expression by RPPA, immunoblot, and flow cytometry. DDR targeting significantly increased the total level of PD-L1 protein in all cell lines tested with the greatest PD-L1 fold change (up to 5 fold) with prexasertib. | Cancer Discov. 2019 May;9(5):646-661. |
H82 | 30 nM | 72 hours | To evaluate the cytotoxic effects of Prexasertib in combination with cisplatin on SCLC cell lines, results showed that Prexasertib significantly enhanced cisplatin cytotoxicity. | J Thorac Oncol. 2019 Jun;14(6):1032-1045. |
GLC4 | 30 nM | 72 hours | To evaluate the cytotoxic effects of Prexasertib in combination with cisplatin on SCLC cell lines, results showed that Prexasertib significantly enhanced cisplatin cytotoxicity. | J Thorac Oncol. 2019 Jun;14(6):1032-1045. |
D425 | 15 nM | 72 hours | Evaluate the synergistic effect of Prexasertib with DNA-damaging chemotherapies, results showed Prexasertib significantly enhanced the cytotoxicity of chemotherapies | Sci Transl Med. 2021 Jan 20;13(577):eaba7401. |
D283 | 12 nM | 72 hours | Evaluate the synergistic effect of Prexasertib with DNA-damaging chemotherapies, results showed Prexasertib significantly enhanced the cytotoxicity of chemotherapies | Sci Transl Med. 2021 Jan 20;13(577):eaba7401. |
NSCLC cell lines | >0.8 µM | Evaluate the antiproliferative effect of LY2606368 on NSCLC cell lines, which were resistant to LY2606368 | Cancer Res. 2017 Jul 15;77(14):3870-3884. | |
OSKG | 6.5 nM | Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 6.5 nM and IC100 of 20 nM. | Int J Cancer. 2020 Aug 15;147(4):1059-1070. | |
OSRH-2011/5 | 2 nM | Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 2 nM and IC100 of 7 nM. | Int J Cancer. 2020 Aug 15;147(4):1059-1070. | |
SAOS-2 | 3 nM | Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 3 nM and IC100 of 10 nM. | Int J Cancer. 2020 Aug 15;147(4):1059-1070. | |
KHOS-240S | 1.7 nM | Prexasertib alone resulted in strongly reduced clonogenic survival, with IC50 of 1.7 nM and IC100 of 7 nM. | Int J Cancer. 2020 Aug 15;147(4):1059-1070. |
In Vivo:
Administration | Dosage | Frequency | Description | References |
CB-17 SCID beige mice | Cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models | Subcutaneous injection | 10 mg/kg | Twice daily for 3 days followed by 4 days rest for 3-4 weeks | Evaluate the anti-tumor effects of Prexasertib as a monotherapy or in combination with chemotherapy in multiple preclinical models of pediatric cancer. Results showed Prexasertib exhibited significant anti-tumor activity, including complete and partial regressions. | Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. |
Mice | Immunocompetent SCLC model (RPP/mTmG flank tumors) | Subcutaneous injection | 10 mg/kg | 2 days per week, twice daily, for 3 weeks | Evaluated the anti-tumor effect of prexasertib in combination with anti-PD-L1 antibody. Remarkable tumor regression was observed in the combination treated group within 1 week, with complete response in 6/10 mice. | Cancer Discov. 2019 May;9(5):646-661. |
C57BL/6 mice | Subcutaneous Hepa1-6 xenograft model | Subcutaneous injection | 10 mg/kg | Twice daily for 2 days followed by 5 days rest, repeated weekly for 3 weeks | To investigate the anti-tumor effects of Prexasertib on Hepa1-6 subcutaneous xenografts, results showed that Prexasertib inhibited tumor growth, increased tumor cell apoptosis, and promoted NK cell infiltration. | Br J Cancer. 2021 Jul;125(1):101-111. |
NCr mice | Ewing sarcoma xenograft model | Subcutaneous injection | 10 mg/kg | Twice daily for 3 days, repeated after an 11-day interval | To evaluate the effect of Prexasertib alone or in combination with gemcitabine on tumor growth and mouse survival. Results showed that Prexasertib alone caused tumor regression, and the combination with gemcitabine significantly prolonged mouse survival. | Mol Cancer Ther. 2018 Dec;17(12):2676-2688. |
NSGS mice | SF3B1/RUNX1-mutant MDS patient iPSC-derived HSPCs | Subcutaneous injection | 10 mg/kg | Twice daily for 3 consecutive days followed by 4 days of rest, repeated for 3 weeks | Prexasertib selectively eradicated SF3B1-mutant HSPCs, significantly reducing the proportion of engrafted SF3B1-mutant cells | Blood Cancer Discov. 2024 Sep 3;5(5):353-370 |
Nude mice | AML xenograft model | Subcutaneous injection | 10 mg/kg or 15 mg/kg | Every 12 hours on days 1–3, 8–10, 15–17 and 22–24 | Evaluated the antileukemic effects of Prexasertib in vivo, showing dose-dependent inhibition of xenograft growth and enhanced host survival | Cancer Res. 2021 May 15;81(10):2666-2678. |
Nude mice | SCLC syngeneic model | Subcutaneous injection | 10 mg/kg, twice daily | 3 days per week for 3 weeks | Evaluate the antitumor effect of LY2606368 monotherapy in SCLC models, with 6 mice showing complete response and 3 mice showing >75% tumor reduction | Cancer Res. 2017 Jul 15;77(14):3870-3884. |
Rats | T8 dorsal column (DC) crush injury model | Intrathecal injection | 2 μg | Once weekly for 6 weeks | Prexasertib significantly suppressed Chk2 phosphorylation, promoted axon regeneration/sprouting, and restored sensory and locomotor function after spinal cord injury. | Sci Adv. 2022 Sep 16;8(37):eabq2611. |
Mice | D425 MB orthotopic xenografts | Intravenous injection | 20 mg/kg | Once weekly for 6 weeks | Evaluate the anti-tumor effect of Prexasertib combined with cyclophosphamide, results showed the combination therapy significantly extended the survival of mice | Sci Transl Med. 2021 Jan 20;13(577):eaba7401. |
BALB/C nude mice | SK-UT-1 tumor model | Intraperitoneal injection | 3 mg/kg Prexasertib + 3 mg/kg Cisplatin | Twice a week for four weeks | To evaluate the antitumor effect of Prexasertib in combination with cisplatin, results showed that the combination therapy significantly inhibited tumor proliferation and prolonged the time to tumor progression. | Clin Cancer Res. 2022 May 13;28(10):2147-2159. |
Nude mice | SCLC xenograft model | Subcutaneous injection | 5 mg/kg | Twice daily for 3 days followed by 4 days of rest for a total of 3 cycles | To evaluate the antitumor activity of Prexasertib alone or in combination with cisplatin in SCLC xenograft models, results showed that Prexasertib significantly enhanced cisplatin antitumor activity and overcame cisplatin resistance. | J Thorac Oncol. 2019 Jun;14(6):1032-1045. |
Immunocompromised mice | CRC-SCs xenograft model | Subcutaneous injection | 5 mg/kg or 10 mg/kg | Three cycles of three consecutive days, twice daily, followed by 4 days of rest | Evaluate the inhibitory effect of LY2606368 on the growth of CRC-SCs xenografts, showing LY2606368 significantly inhibits tumor growth in sensitive CRC-SCs. | Gut. 2018 May;67(5):903-917. |
NSG mice | HGSOC PDX models | Subcutaneous injection | 8 mg/kg | Twice daily for 3 days, followed by four days of rest and repeated for two additional cycles | To evaluate the anti-tumor activity of Prexasertib in HGSOC PDX models, results showed that Prexasertib monotherapy demonstrated significant anti-tumor activity across all models. | Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02735980 | Small Cell Lung Cancer | PHASE2 | COMPLETED | 2019-02-12 | Highlands Oncology Group, Faye... More >>tteville, Arkansas, 72703, United States|Yale University School of Medicine, New Haven, Connecticut, 06520, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|Florida Cancer Specialists, Fort Myers, Florida, 33908, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, 33705, United States|Massachusetts General Hospital, Danvers, Massachusetts, 01923, United States|Washington University Medical Center, Saint Louis, Missouri, 63110, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0001, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, 37404, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232-6307, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besancon Cedex, 25030, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, 59037, France|"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Montpellier, 34070, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vantoux, 57070, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, 06120, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, 11527, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, 71110, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, 26504, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Seoul, 06351, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, 120-792, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, 1066 CX, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, 4818 CK, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zwolle, 8025 AB, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, 08035, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, 28034, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaragoza, 50009, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antalya, 07059, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edirne, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, 34098, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, 35100, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, 38039, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dnipropetrovsk, 49102, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kharkiv, 61070, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sumy, 40005, Ukraine|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Headington, OX3 7LJ, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, LE1 5WN, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, S10 2SJ, United Kingdom Less << |
NCT01115790 | Advanced Cancer|Squamous Cell ... More >>Carcinoma|Carcinoma, Squamous Cell of Head and Neck|Lung Squamous Cell Carcinoma Stage IV|Anal Squamous Cell Carcinoma|Carcinoma, Non-Small-Cell Lung Less << | PHASE1 | COMPLETED | 2025-01-16 | Florida Cancer Specialists, Sa... More >>rasota, Florida, 34232, United States|Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less << |
NCT02514603 | Neoplasm | PHASE1 | COMPLETED | 2017-04-10 | For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, 277 8577, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, 104-0045, Japan Less << |
NCT03414047 | Ovarian Cancer | PHASE2 | COMPLETED | 2020-10-03 | Arizona Oncology Associates, P... More >>.C., Tucson, Arizona, 85711, United States|Kaiser Permanente Medical Center, Vallejo, California, 94589, United States|University of Southern Florida School of Medicine, Gainesville, Florida, 32610-0296, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Research Medical Center, Kansas City, Missouri, 63142, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0001, United States|Cancer Care Associates, Tulsa, Oklahoma, 74146, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|Rhode Island Hospital, Providence, Rhode Island, 02903, United States|Sioux Valley Clinic, Sioux Falls, South Dakota, 57104, United States|University of Tennessee Medical Center, Knoxville, Tennessee, 37920, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, 37203, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Concord Repatriation General Hospital, Concord, New South Wales, 2139, Australia|Prince of Wales Hospital, Randwick, New South Wales, 2031, Australia|Westmead Hospital, Wentworthville, New South Wales, 2145, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, 4029, Australia|Mater Adult Hospital Brisbane, South Brisbane, Queensland, 4101, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Burnside War Memorial Hospital, Toorak Gardens, South Australia, 5065, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Institut Jules Bordet, Brussel, 1000, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, 3000, Belgium|GZA St Augustinus, Wilrijk, 2610, Belgium|Rambam Medical Center, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Sheba Medical Center, Ramat Gan, 5265601, Israel|Policlinico Univ. Agostino Gemelli, Roma, Lazio, 00168, Italy|Istituto Europeo di Oncologia, Milano, Milan, 20141, Italy|Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, 80131, Italy|Samsung Medical Center, Seoul, Korea, 06351, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, 120-792, Korea, Republic of|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Ramon y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|University College Hospital - London, London, Greater London, NW1 2BU, United Kingdom|Christie NHS Foundation Trust, Manchester, Greater Manchester, M20 4BX, United Kingdom|Mount Vernon Hospital, Northwood, Middlesex, HA6 2RN, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, GU2 7XX, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, United Kingdom|Northampton General Hospital, Northampton, NN1 5BD, United Kingdom Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.74mL 0.55mL 0.27mL |
13.68mL 2.74mL 1.37mL |
27.37mL 5.47mL 2.74mL |